Global Patent Index - EP 4236963 A1

EP 4236963 A1 20230906 - 5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER

Title (en)

5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER

Title (de)

5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO CHOLESTAN-3BETA-OL ANALOGE UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS

Title (fr)

ANALOGUES DU 5ALPHA-HYDROXY-6 BETA-[2-(1-H-IMIDAZOL-4-YL)ETHYLAMINO]-CHOLESTAN-3 BETA-OL ET COMPOSITIONS PHARMACEUTIQUES LE COMPRENANT POUR UTILISATION DANS LE TRAITEMENT DU CANCER

Publication

EP 4236963 A1 20230906 (FR)

Application

EP 21801547 A 20211028

Priority

  • BE 202005764 A 20201029
  • BE 202005878 A 20201203
  • EP 2021080054 W 20211028

Abstract (en)

[origin: WO2022090427A1] The present invention relates to a novel compound of general formula (I), and/or a pharmaceutically acceptable salt of such a compound, a pharmaceutical composition comprising at least said compound, for use as a drug for shrinking cancerous tumours in mammals.

IPC 8 full level

A61K 31/575 (2006.01); A61K 31/24 (2006.01); A61K 31/36 (2006.01); A61K 31/58 (2006.01); A61K 31/704 (2006.01); A61K 33/24 (2019.01); A61K 33/36 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)

CPC (source: EP KR US)

A61K 31/24 (2013.01 - EP); A61K 31/36 (2013.01 - EP); A61K 31/575 (2013.01 - EP); A61K 31/58 (2013.01 - EP KR); A61K 31/704 (2013.01 - EP); A61K 45/06 (2013.01 - EP US); A61P 35/00 (2018.01 - EP KR); A61P 35/02 (2018.01 - EP KR US); C07J 43/003 (2013.01 - US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022090427 A1 20220505; AU 2021372797 A1 20230615; AU 2021372797 A2 20230629; AU 2021372797 A9 20241003; CA 3196518 A1 20220505; EP 4236963 A1 20230906; JP 2023551363 A 20231208; KR 20230097077 A 20230630; US 2023391817 A1 20231207

DOCDB simple family (application)

EP 2021080054 W 20211028; AU 2021372797 A 20211028; CA 3196518 A 20211028; EP 21801547 A 20211028; JP 2023526224 A 20211028; KR 20237017165 A 20211028; US 202118034317 A 20211028